Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,084.75
(
-0.34%
)
US TECH 100
25,820.80
(
-0.20%
)
Dow Jones
49,338.13
(
-0.22%
)
Brent Oil
94.96
(
4.73%
)
Bitcoin
75,623.78
(
-0.35%
)
News Focus
News Focus
Post# of 822237
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

sentiment_stocks

Send PM Follow Ignore
Followers 238
Posts 15501
Boards Moderated 1
Alias Born 03/29/2014

sentiment_stocks

Member Level

Re: S_mack post# 706027

Sunday, 07/14/2024 9:47:37 PM

Sunday, July 14, 2024 9:47:37 PM

Post# of 822237
I do not believe the other companies with their GBM trials would be motivated to share their trial data. As we can see from ECA data shown in the JAMA article, the DCVax-L trial data beat the other trial’s data, so it likely would NOT have weakened the NWBO trial results.

Additionally, does anyone really think Linda Powers would be willing to share the DCVax-L P3 patient level data with a competitor?

lol, no way, IMO. :)
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News